Nycomed and Norgine sign a Licence Agreement for MOVIPREP® in Russia and the Commonwealth of Independent States (CIS)
(Thomson Reuters ONE) -
Nycomed /
Nycomed and Norgine sign a Licence Agreement for MOVIPREP® in Russia and the
Commonwealth of Independent States (CIS)
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Nycomed and Norgine, a European specialty pharmaceutical company, today
announced that they have entered into a licensing agreement that gives Nycomed
the exclusive rights to commercialise MOVIPREP, the worlds leading bowel
cleansing brand, in Russia, Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan,
Kyrgyzstan, Moldova, Mongolia, Tajikistan, Turkmenistan, Ukraine, and
Uzbekistan.
Moviprep is an osmotic laxative for bowel cleansing prior to any clinical
procedure requiring a clean bowel, such as colonoscopy. MOVIPREP will be subject
to regulatory review and approval and Nycomed will conduct the necessary steps
for approval. Financial details of the agreement were not disclosed.
We are very pleased to further expand our recently established gastrointestinal
product portfolio with MOVIPREP," said Jostein Davidson, Senior Vice President,
Nycomed Group, and President, Nycomed Russia-CIS. "MOVIPREP has proven to be the
preferred choice for bowel preparation in EU and Nycomed is proud to make this
product a success in Russia/CIS improving quality of life of millions of
patients."
Norgine's CEO, Peter Stein said: "This is an important agreement for Norgine as
it will mark our entry into this fast developing market. We look forward to
working with Nycomed to capitalise on their extensive sales and distribution
network to help realise MOVIPREP's potential in the CIS."
MOVIPREP is marketed by Norgine through its own Sales and Marketing organisation
and by Salix Pharmaceuticals in the USA, by Medical Futures in Canada, by
PharmaSwiss in Central and Eastern Europe and is under development with
Ajinomoto in Japan.
About Norgine
Norgine is an independent, successful European speciality pharmaceutical company
that has been established for over 100 years and has a presence in all major
European markets. In 2010, Norgine's net product sales were ?258 million. The
Company employs over 1,200 people.
Norgine's focus is the development and marketing of pharmaceutical products that
address significant unmet clinical needs in therapeutic areas such as
gastroenterology, hepatology and supportive care. The Company currently markets
a range of products in various markets in its key therapeutic areas e.g.,
MOVICOL® for the treatment of constipation and faecal impaction, MOVIPREP® a
bowel cleansing preparation, KLEAN-PREP® for bowel preparation prior to
colonoscopy, XIFAXAN® for the treatment of travellers diarrhoea and ORAMORPH®
for the treatment of moderate to severe pain associated with cancer.
Norgine is active in research and development and currently has products in
various stages of clinical development. Norgine manufactures most of its own
products in Hengoed, UK and Dreux, France.
About Nycomed
Nycomed is a privately owned global pharmaceutical company with a diversified
portfolio focused on branded medicines in gastroenterology, respiratory and
inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC
products completes the portfolio.
Its R&D is structured around collaborations. In-licensing and expanding in
emerging markets are cornerstones of the company's growth strategy.
Nycomed employs 12,500 associates worldwide, and its products are sold in more
than 100 countries. It has strong platforms in Europe and in fast-growing
markets such as Russia/CIS, Latin America, Asia and the Middle East. In the US
and Japan its products are available through best in class partners.
Headquartered in Zurich, Switzerland, the company generated total sales of
? 3.2 billion in 2010 and an adjusted EBITDA of ? 851 million.
For more information visitwww.nycomed.com
For further information
Media:
General phone: +41 44 555 15 10
Tobias Cottmann, phone: +41 44 555 15 01
Investors:
Christian B. Seidelin, phone: +41 44 555 11 04
Norgine Contact:
Julie Hornby Winfield, phone: +44 1895 826600
jhornbywinfield(at)norgine.com
This press release has been issued by Nycomed International Management GmbH,
Thurgauerstrasse 130, CH-8152 Glattpark-Opfikon, Zurich, Switzerland.
--- End of Message ---
Nycomed
Thurgauerstrasse 130 Glattpark-Opfikon Switzerland
Press Release Nycomed Norgine DE:
http://hugin.info/144179/R/1540016/470739.pdf
Press Release Nycomed Norgine EN:
http://hugin.info/144179/R/1540016/470738.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Nycomed via Thomson Reuters ONE
[HUG#1540016]
Unternehmensinformation / Kurzprofil:
Datum: 22.08.2011 - 09:59 Uhr
Sprache: Deutsch
News-ID 57637
Anzahl Zeichen: 5713
contact information:
Town:
Glattpark-Opfikon
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 239 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nycomed and Norgine sign a Licence Agreement for MOVIPREP® in Russia and the Commonwealth of Independent States (CIS)"
steht unter der journalistisch-redaktionellen Verantwortung von
Nycomed (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
